Progression-free survival
Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma
... sponse, progression free survival and overall survival were registered in a clinical ...database. Survival times were calculated as the time from diagnosis to an event ...
8
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
... tumor, survival, disease progression, cancer survival, survival time, survival rate, progression, progression-free survival, time to progres- sion, time to ...
10
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
... overall survival (OS) is often used as a primary endpoint despite its several points of ...of progression-free survival (PFS) in the first three lines of treatment as a potential surrogate ...
5
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
... in progression-free survival (PFS); how- ever, few have reported improvement in overall survival ...to progression (TTP) for OS has not been formally investigated in HR+, HER2– ...
10
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study
... of progression-free survival (PFS) as an intermediate endpoint to overall survival (OS) has grown in recent years, due to the challenges in demonstrating an OS benefit within clinical trials ...
7
Challenges and methodologies in using progression free survival as a surrogate for overall survival In oncology
... Outcomes from clinical and other healthcare trials of most interest to patients and health systems are usually increases in the length and quality of life as a result of treatment. This poses a problem, because to ...
24
Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
... Our results suggest that PFS may serve as an intermediate endpoint for OS. However, this analysis had some unavoidable limitations. It is worth noting that patients enrolled in these stud- ies were required to meet the ...
8
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
... Cross-over is present in RECORD-1 and TARGET studies. Hence, cross-over has an impact on cabozantinib vs axitinib and BSC comparisons. However, comparison to nivolumab is not impacted by the cross-over issue. In the ...
24
Abstract Background and Objectives: ovarian cancer comprise 4% of all women cancer and 34% amongst
... year progression free survival rate of 36 vs ...overall survival rate of 69 vs 88% ...overall survival difference in both the group is ...
6
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
... IRAEs are thought to represent bystander effects from activated T-cells and it is plausible that patients responding to ICIs would have greater likelihood of autoimmune toxicities (e.g. due to a more ...
11
The Initial Area Under the Curve Derived from Dynamic Contrast Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter
... overall survival and progression-free survival were assessed with log-rank tests, according to the MGMT ...overall survival and progression-free survival models ...
8
Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer
... longer progression free survival (PFS) with high TMB than low TMB ...overall survival (OS) was significantly lon- ger in high TMB than low TMB ...
10
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
... Results: Presence of AEs in the first 4 weeks was associated with prolonged median overall survival (169 vs. 103 days, log-rank p = 0.0039; adjusted hazard ratio (HR) 0.64, 95% confidence interval [CI] 0.64 – ...
9
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
... W e investigated extramedullary disease in newly diagnosed mul- tiple myeloma patients and its impact on outcome following first-line autologous stem cell transplantation. We identified 3744 adult myeloma patients who ...
8
Original Article Prognostic significance of CD4/CD8 ratio in patients with breast cancer
... and survival rates were analyzed by the Kaplan-Meier method, log-rank test and multivariate Cox proportional hazards ...metastasis-free survival (DMFS, P<0.001) and progression-free ...
7
Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis
... MAGE-A: Melanoma-associated antigens A; PPIC: Peptidylprolyl isomerase C (cyclophilin C); GPX8: Glutathione peroxidase 8; CDH3: Cadherin-3; TUSC3: Tumor suppressor candidate 3; COL3A1: Collagen, type III, alpha 1; LAMB1: ...
10
Early Stage Triple Negative Breast Cancer Has Significantly Better Outcomes than More Advanced Disease: A Single Centre Retrospective Review
... on progression free and overall ...superior progression free and overall survival when compared to more advanced ...and progression free survival suggest that the ...
10
Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
... Background: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and ...
8
Infarct volume after glioblastoma surgery as an independent prognostic factor
... From our database 529 consecutive glioblastoma patients were identified. 251 patients with surgeries for a newly diagnosed glioblastoma (WHO IV) between May 2008 and September 2015 with preoperative and early ...
10
38-month long progression-free and symptom-free survival of a patient with recurrent glioblastoma multiforme: A case report of the Paleolithic Ketogenic Diet (PKD) used as a stand-alone treatment after failed standard oncotherapy
... In recent years there has been a surge of interest in the use of ketogenic diets as a potential treatment for cancer (Klement, 2017). The idea that ketogenic diets may have antitumor effects was initially put forward ...
13